[go: up one dir, main page]

EA201000879A1 - Производные пиразола и их применение в качестве ингибиторов циклинзависимости киназ - Google Patents

Производные пиразола и их применение в качестве ингибиторов циклинзависимости киназ

Info

Publication number
EA201000879A1
EA201000879A1 EA201000879A EA201000879A EA201000879A1 EA 201000879 A1 EA201000879 A1 EA 201000879A1 EA 201000879 A EA201000879 A EA 201000879A EA 201000879 A EA201000879 A EA 201000879A EA 201000879 A1 EA201000879 A1 EA 201000879A1
Authority
EA
Eurasian Patent Office
Prior art keywords
derivatives
kinaz
pyrazoles
cyclin
dependence
Prior art date
Application number
EA201000879A
Other languages
English (en)
Other versions
EA018459B1 (ru
Inventor
Кристофер Томас Брейн
Ён Шин Цо
Йин Хоу
Му Сун
Original Assignee
Новартис Аг
Астекс Терапьютикс Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг, Астекс Терапьютикс Лтд. filed Critical Новартис Аг
Publication of EA201000879A1 publication Critical patent/EA201000879A1/ru
Publication of EA018459B1 publication Critical patent/EA018459B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

В заявке описаны органические соединения, которые применимы для лечения, предупреждения и/или облегчения протекания заболеваний, в частности, описаны пиразолы, которые ингибируют протеинкиназы. Органические соединения применимы для лечения пролиферативного заболевания.
EA201000879A 2007-12-07 2008-12-08 Производные пиразола и их применение в качестве ингибиторов циклинзависимых киназ EA018459B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1227607P 2007-12-07 2007-12-07
PCT/EP2008/067037 WO2009071701A1 (en) 2007-12-07 2008-12-08 Pyrazole derivatives and use thereof as inhibitors of cyclin dependent kinases

Publications (2)

Publication Number Publication Date
EA201000879A1 true EA201000879A1 (ru) 2010-12-30
EA018459B1 EA018459B1 (ru) 2013-08-30

Family

ID=40343520

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201000879A EA018459B1 (ru) 2007-12-07 2008-12-08 Производные пиразола и их применение в качестве ингибиторов циклинзависимых киназ

Country Status (15)

Country Link
US (1) US8367687B2 (ru)
EP (1) EP2231636B1 (ru)
JP (1) JP2011506303A (ru)
KR (1) KR20100098521A (ru)
CN (1) CN101883764B (ru)
AT (1) ATE524459T1 (ru)
AU (1) AU2008333136B2 (ru)
BR (1) BRPI0821151A2 (ru)
CA (1) CA2707989A1 (ru)
EA (1) EA018459B1 (ru)
ES (1) ES2374480T3 (ru)
MX (1) MX2010006203A (ru)
PL (1) PL2231636T3 (ru)
PT (1) PT2231636E (ru)
WO (1) WO2009071701A1 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2822389C2 (ru) * 2014-10-13 2024-07-04 Юхан Корпорейшн Соединения и композиции для модуляции киназной активности мутантов egfr

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR069165A1 (es) 2007-11-05 2010-01-06 Novartis Ag Derivados de 4-bencilamino-1-carboxacilpiperidina como inhibidores de cetp utiles para el tratamiento de hiperlipidemia
WO2009071509A1 (en) 2007-12-03 2009-06-11 Novartis Ag 1,2-disubstituted-4-benzylamino-pyrrolidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperli pidemia or arteriosclerosis
CA2760911A1 (en) * 2009-05-19 2010-11-25 George E. Davis Compounds and methods for controlling fungi
CA2800327A1 (en) * 2010-04-13 2011-10-20 Novartis Ag Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase 6 (cdk4/6) inhibitor and an mtor inhibitor for treating cancer
HUE029196T2 (en) 2010-06-04 2017-02-28 Hoffmann La Roche Aminoprimidine derivatives as LRRK2 modulators
GB201017345D0 (en) 2010-10-14 2010-11-24 Proximagen Ltd Receptor antagonists
US8815882B2 (en) 2010-11-10 2014-08-26 Genentech, Inc. Pyrazole aminopyrimidine derivatives as LRRK2 modulators
CA2830882C (en) 2011-03-22 2021-03-16 Dinesh Barawkar Substituted fused tricyclic compounds, compositions and medicinal applications thereof
WO2013055949A2 (en) 2011-10-11 2013-04-18 Dana Farber Cancer Institute, Inc. Pyrazol-3-ones that activate pro-apoptotic bax
US9593115B2 (en) 2012-09-21 2017-03-14 Advinus Therapeutics Ltd. Substituted fused tricyclic compounds, compositions, and medicinal applications thereof
CN104918919A (zh) 2012-11-21 2015-09-16 Ptc医疗公司 取代的反向嘧啶Bmi-1抑制剂
NZ748260A (en) 2013-08-30 2020-01-31 Ptc Therapeutics Inc Substituted pyrimidine bmi-1 inhibitors
WO2015076800A1 (en) 2013-11-21 2015-05-28 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine bmi-1 inhibitors
BR112017019437A2 (pt) 2015-04-02 2018-05-02 Proximagen Ltd terapias para câncer
DK3331877T3 (da) * 2015-08-04 2022-01-03 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Pyrazolpyrimidinderivat og anvendelser deraf
SMT202200134T1 (it) 2018-03-08 2022-05-12 Incyte Corp Composti di amminopirazindiolo come inibitori di pi3k-y
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
EP3836932A2 (en) 2018-08-17 2021-06-23 PTC Therapeutics, Inc. Method for treating pancreatic cancer
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
WO2020223558A1 (en) 2019-05-01 2020-11-05 Incyte Corporation Tricyclic amine compounds as cdk2 inhibitors
CA3150681A1 (en) 2019-08-14 2021-02-18 Incyte Corporation Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
WO2021072232A1 (en) 2019-10-11 2021-04-15 Incyte Corporation Bicyclic amines as cdk2 inhibitors
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6979686B1 (en) * 2001-12-07 2005-12-27 Pharmacia Corporation Substituted pyrazoles as p38 kinase inhibitors
GB9919778D0 (en) * 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
ATE407132T1 (de) 2000-12-05 2008-09-15 Vertex Pharma Inhibitoren von c-jun n-terminalen kinasen (jnk) und anderen proteinkinasen
GB0107901D0 (en) 2001-03-29 2001-05-23 Cyclacel Ltd Anti-cancer compounds
JP4316893B2 (ja) * 2001-05-16 2009-08-19 バーテックス ファーマシューティカルズ インコーポレイテッド Ｓｒｃおよび他のプロテインキナーゼのインヒビター
DE60210819T2 (de) * 2001-12-17 2007-04-19 Smithkline Beecham Corp. Pyrazolopyridazinderivate
GB0215844D0 (en) 2002-07-09 2002-08-14 Novartis Ag Organic compounds
WO2004035588A1 (en) 2002-10-15 2004-04-29 Smithkline Beecham Corporation Pyradazine compounds as gsk-3 inhibitors
GB0409080D0 (en) * 2004-04-23 2004-05-26 Biofocus Discovery Ltd Compounds which interact with protein kinases
EP1917258A2 (en) 2005-08-26 2008-05-07 SmithKline Beecham Corporation Pyrimidinyl-pyrazole inhibitors of aurora kinases
JP5525812B2 (ja) * 2006-04-19 2014-06-18 メルク セローノ ソシエテ アノニム Ｍｅｋインヒビターとしての新規ヘテロアリール置換アリールアミノピリジン誘導体
WO2007132220A1 (en) 2006-05-12 2007-11-22 Cyclacel Limited Combination of a 2-substituted-4-heter0aryl-pyrimidine amine with a cytotoxic drug and use thereof in the treatment of a proliferative disorder
EA201070143A1 (ru) * 2007-07-13 2010-08-30 Аддекс Фарма С.А. Новые гетероароматические производные и их использование в качестве положительных аллостерических модуляторов метаботропных глутаматных рецепторов

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2822389C2 (ru) * 2014-10-13 2024-07-04 Юхан Корпорейшн Соединения и композиции для модуляции киназной активности мутантов egfr

Also Published As

Publication number Publication date
BRPI0821151A2 (pt) 2015-06-16
EP2231636A1 (en) 2010-09-29
CN101883764B (zh) 2013-11-13
ES2374480T3 (es) 2012-02-17
CA2707989A1 (en) 2009-06-11
KR20100098521A (ko) 2010-09-07
MX2010006203A (es) 2010-06-25
PL2231636T3 (pl) 2012-04-30
US20100280033A1 (en) 2010-11-04
JP2011506303A (ja) 2011-03-03
AU2008333136A1 (en) 2009-06-11
PT2231636E (pt) 2012-01-02
WO2009071701A1 (en) 2009-06-11
ATE524459T1 (de) 2011-09-15
US8367687B2 (en) 2013-02-05
EP2231636B1 (en) 2011-09-14
AU2008333136B2 (en) 2012-05-10
CN101883764A (zh) 2010-11-10
EA018459B1 (ru) 2013-08-30

Similar Documents

Publication Publication Date Title
EA201000879A1 (ru) Производные пиразола и их применение в качестве ингибиторов циклинзависимости киназ
JO3235B1 (ar) مركبات بيررولوبيريميدين و استعمالاتها
EA200900798A1 (ru) Производные индол-4-илпиримидинил-2-иламина и их применение в качестве ингибиторов циклинзависимой киназы
EA200900819A1 (ru) Хиназолины для ингибирования pdk1
EA200970738A1 (ru) Ингибиторы активности akt
TW200801008A (en) Protein kinase inhibitors
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
BRPI0807717A2 (pt) Inibidores de quinase úteis para o tratamento de doenças mieloproliferativas e outras doenças proliferativas.
EA200971077A1 (ru) Гетероциклические модуляторы киназы
DE602007004092D1 (de) C-met-proteinkinasehemmer zur behandlung proliferativer erkrankungen
MX2009006706A (es) Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
ATE534633T1 (de) Indazolderivate zur behandlung von hsp90- induzierten krankheiten
EA201170252A1 (ru) Амидофеноксиндазолы в качестве ингибиторов c-мет
EA200970403A1 (ru) Бициклические триазолы в качестве модуляторов протеинкиназы
ECSP088561A (es) Derivados de pirimidinil-aril-urea que son inhibidores de fgf
EA201170349A1 (ru) Модуляторы mif
EA201391682A1 (ru) Замещенные производные индазола, активные в качестве ингибиторов киназы
ECSP099414A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteína quinasa
MX2009006536A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
EA200901144A1 (ru) Ингибиторы киназы pim и способы их применения
EA201001860A1 (ru) Ингибиторы дпп-4 для лечения неалкогольной жировой дистрофии печени
EA201270535A1 (ru) Пуриновые производные, применимые в качестве ингибиторов hsp90
EA201170834A1 (ru) Соединения, пригодные для ингибирования chk1
NZ590550A (en) Inhibitors of Apoptosis (IAP) for treating cancer
NO20084747L (no) Tetrahydropteridiner anvendbare som inhibitorer av protein kinaser

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY KZ RU